Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
National Center for Research Resources (NCRR)
With
National Institute of Allergy and Infectious Diseases (NIAID)
Rockefeller University
PROTOCOL OUTLINE: This is a randomized, double blind study. Patients are stratified by type of infection.
Patients are randomly assigned to oral thalidomide or placebo. Therapy is administered daily for up to 8 weeks, beginning the night before antitubercular treatment is initiated.
Age
18–65
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
PROTOCOL ENTRY CRITERIA:
-Disease Characteristics--
Human immunodeficiency virus (HIV) or mycobacterial infection that requires at least 10 days of inpatient antitubercular treatment
Mycobacterial infection confirmed by positive acid-fast bacilli smear or culture for Mycobacterium tuberculosis
At least 1 of the following signs and symptoms required:
Temperature over 38 degrees C on at least 2 occasions within 1 week prior to treatment
Weight loss greater than 5 kg
Pulmonary involvement in at least 1 lobe on x-ray
Night sweats on at least 2 occasions within 1 week prior to treatment
-Prior/Concurrent Therapy--
Concurrent rifampicin, isoniazid, pyrazinamide, and ethambutol for tuberculosis allowed
-Patient Characteristics--
No neuropathy and not at risk for neuropathy
Not pregnant
Negative pregnancy test
Fertile patients must use effective contraception during and for 4 weeks after study
